BridgeBio Pharma (NASDAQ:BBIO) highlighted accelerating U.S. uptake for its transthyretin (TTR) stabilizer Attruby and laid out key timelines for upcoming launches and pipeline programs during a ...
BridgeBio Pharma Inc. (NASDAQ:BBIO) is one of the stocks with explosive growth potential. On February 24, BridgeBio Pharma reported a transformative full-year 2025, marked by a surge in total revenue ...
BridgeBio Pharma Inc. BBIO is drawing renewed investor attention as the biotech company advances a slate of rare-disease therapies toward potential regulatory filings and commercial launches. William ...
6don MSN
Truist raises its price target on BridgeBio Pharma, Inc. (BBIO) to $95 and maintains a buy rating
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is among the 10 Fastest Growing NASDAQ Stocks to Buy. On February 25, 2026, Truist analyst Danielle Brill raised the firm’s price target on BridgeBio Pharma, Inc.
BridgeBio reports strong demand for Attruby post-FDA approval and enrollment completion in three Phase 3 trials, with significant financial backing. BridgeBio Pharma, Inc. announced significant ...
-Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR. Attruby has been shown to preserve the native function of TTR as a transport protein of ...
PALO ALTO, Calif., Nov. 22, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a new type of biopharmaceutical company focused on genetic diseases, today ...
- Attruby demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date: - In as few as 3 months, the time to first event (all-cause mortality (ACM) or cardiovascular-related ...
Aktien»Nachrichten»BRIDGEBIO PHARMA AKTIE»BridgeBio Pharma, Inc.: Attruby (acoramidis), a Near Complete TTR Stabilizer (=90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results